Open AccessThis article is
- freely available
Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
Adelaide Proteomics Centre, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia
Research Centre for Reproductive Health, School of Paediatrics and Reproductive Health, Robinson Institute, University of Adelaide, Adelaide, Australia
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, Australia
* Author to whom correspondence should be addressed.
Received: 30 November 2010; Accepted: 12 January 2011 / Published: 14 January 2011
Abstract: Most scientific efforts towards early detection of ovarian cancer are commonly focused on the discovery of tumour-associated antigens (TAA). Autologous antibodies against TAA, however, may serve as more sensitive diagnostic markers. They circulate in the blood before TAA and are usually more abundant than the TAAs themselves as a result of amplification through the humoral immune response. Accumulating evidence also suggests that a humoral response already exists during malignant transformation when aberrant gene expression is translated into premalignant cellular changes. This article reviews the current knowledge about autoantibodies against TAA in ovarian cancer and presents current immunoproteomic approaches for their detection.
Keywords: ovarian cancer; autoantibodies; immunoproteomics
Citations to this Article
Cite This Article
MDPI and ACS Style
Martin, K.; Ricciardelli, C.; Hoffmann, P.; Oehler, M.K. Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery. Int. J. Mol. Sci. 2011, 12, 410-428.
Martin K, Ricciardelli C, Hoffmann P, Oehler MK. Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery. International Journal of Molecular Sciences. 2011; 12(1):410-428.
Martin, Karina; Ricciardelli, Carmela; Hoffmann, Peter; Oehler, Martin K. 2011. "Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery." Int. J. Mol. Sci. 12, no. 1: 410-428.